Wedbush Has Lowered Expectations for Edgewise Therapeutics (NASDAQ:EWTX) Stock Price

Edgewise Therapeutics (NASDAQ:EWTX) had its price target decreased by equities research analysts at Wedbush from $53.00 to $51.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush‘s price objective indicates a potential upside of 13.23% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Evercore reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Edgewise Therapeutics in a research report on Monday, July 20th. William Blair began coverage on shares of Edgewise Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Thursday, October 15th. JPMorgan Chase & Co. increased their price target on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Finally, The Goldman Sachs Group raised their price target on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $52.83.

Edgewise Therapeutics Price Performance

EWTX traded up $6.17 during trading on Thursday, reaching $45.04. 3,711,351 shares of the stock traded hands, compared to its average volume of 1,347,881. The stock’s 50-day simple moving average is $40.86 and its two-hundred day simple moving average is $36.54. Edgewise Therapeutics has a fifty-two week low of $16.70 and a fifty-two week high of $48.51. The stock has a market cap of $4.89 billion, a price-to-earnings ratio of 5.50 and a beta of 0.39.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $9.65 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $10.18. Research analysts anticipate that Edgewise Therapeutics will post -2.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kevin Koch sold 17,971 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $43.68, for a total transaction of $784,973.28. Following the completion of the sale, the chief executive officer directly owned 52,488 shares of the company’s stock, valued at approximately $2,292,675.84. This represents a 25.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan J. Russell sold 5,901 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $43.73, for a total transaction of $258,050.73. Following the completion of the transaction, the insider owned 31,466 shares in the company, valued at $1,376,008.18. The trade was a 15.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,329 shares of company stock worth $1,675,529 over the last ninety days. Company insiders own 21.30% of the company’s stock.

Institutional Investors Weigh In On Edgewise Therapeutics

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Edgewise Therapeutics in the second quarter valued at about $268,415,000. Jupiter Topco LLC bought a new position in shares of Edgewise Therapeutics in the second quarter worth about $246,945,000. Janus Henderson Group PLC lifted its position in shares of Edgewise Therapeutics by 29.5% during the 1st quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company’s stock worth $186,289,000 after purchasing an additional 1,348,706 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Edgewise Therapeutics during the 2nd quarter worth about $63,312,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Edgewise Therapeutics by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,219,717 shares of the company’s stock worth $38,413,000 after purchasing an additional 6,060 shares during the last quarter.

More Edgewise Therapeutics News

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: A report of takeover interest appears to be the main near-term catalyst behind the stock’s rise. The report does not establish that a deal has been agreed or that a transaction will occur. Edgewise Therapeutics gains amid report of takeover interest
• Positive Sentiment: The FDA gave favorable feedback on EDG-7500’s Phase 3 plan following an end-of-Phase 2 meeting. The STRATUS-HCM program is designed to study obstructive and nonobstructive HCM and is on track to begin in Q4 2026, reducing uncertainty around the development path. FDA meeting and Phase 3 update
• Neutral Sentiment: Wedbush cut its price target to $51 from $53 but kept an Outperform rating, leaving its view positive despite the modest reduction. Wedbush lowers EWTX price target
• Neutral Sentiment: Edgewise reported quarterly EPS of $9.65, well above the consensus estimate of a loss of $0.53. The unusually large reported figure may need context to assess its relevance to ongoing operations.
• Negative Sentiment: Put-option purchases were unusually high, with 2,813 contracts traded—279% above typical volume. This may reflect increased hedging or bearish positioning, though options activity alone does not confirm investor expectations.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.